Virax Biolabs Group Ltd (VRAX) shareholders
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.00 (-0.65%)
Close on Nov 17, 2026Market cap $257.81KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 1M shares
Institutional holders
0
0 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 823,909 | 9.99% | 13G (passive) | Dec 31, 2025 |
| James Foster | 287,987 | 24.90% | 13G (passive) | Dec 31, 2022 |
Top institutional holders
13F holdings as of Mar 31, 2026
| Holder | Shares | % of VRAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 35,152 | 6.07% | $193.25K | New | 0.00% |
| Jump Financial, LLC | 1,629 | 0.28% | $8.96K | New | 0.00% |
| Osaic Holdings, Inc. | 1 | 0.00% | $4 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 0 | 0M | 0.0% | 0 / 0 | 0 / 3 | 0M | 0M |
| Q1 2026 | 3 | 0M | 6.4% | 2 / 0 | 0 / 4 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.2% | 3 / 1 | 1 / 2 | 0M | 0M |
| Q3 2025 | 4 | 0M | 0.7% | 3 / 1 | 0 / 1 | 0M | 0M |
| Q2 2025 | 2 | 0M | 0.2% | 1 / 1 | 0 / 3 | 0M | 0M |
| Q1 2025 | 4 | 0M | 0.4% | 3 / 0 | 1 / 6 | 0M | 0M |
| Q4 2024 | 7 | 0M | 0.4% | 6 / 1 | 0 / 4 | 0M | 0M |
| Q3 2024 | 5 | 0M | 1.5% | 2 / 3 | 0 / 4 | 0M | 0M |
| Q2 2024 | 7 | 0M | 0.5% | 5 / 1 | 0 / 1 | 0M | 0M |
| Q1 2024 | 3 | 0M | 0.1% | 1 / 1 | 1 / 2 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0.9% | 4 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nigel William McCracken | Chief Operating Officer, Director | – | – | Mar 20, 2026 |
| Jason Davis | Chief Financial Officer | – | – | Mar 18, 2026 |
| James Alexander Cunliffe Foster | Chief Executive Officer | 287,987 | 49.72% | Mar 18, 2026 |
| Nelson M. Haight | Director | – | – | Mar 31, 2026 |
| Evan Michael Norton | Director | – | – | Mar 18, 2026 |
| Iain David Miller | Director | – | – | Mar 18, 2026 |
| Clement Monteil | – | – | – | Oct 21, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
3.17%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-25.6%
From 0M shares
Short volume, 20 days
56.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Virax Biolabs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 216,552 shares on Oct 6, 2026 over the last 90 days.
See a number that looks wrong?